AI in Drug Discovery Market Outlook and Opportunities in Grooming Regions with Forecast 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Artificial Intelligence in Drug Discovery Market” that contains information from 2018 to 2032. 

Market Highlights

The global Artificial Intelligence in Drug Discovery market is accounted to register a CAGR of 29.83% during the forecast period and is estimated to reach USD 5.94 billion by 2032.

Artificial Intelligence (AI) in the drug discovery market refers to the application of advanced computational techniques and machine learning algorithms to accelerate and enhance the process of discovering new drugs. It involves leveraging AI to analyze vast amounts of data, predict drug-target interactions, and optimize drug design, leading to improved efficiency and success rates in the development of new pharmaceuticals.

Key Players

MRFR recognizes the following companies as the key players in the global Artificial Intelligence in Drug Discovery market— IBM (US), Alphabet Inc (US), Atomwise Inc (US), Deep Genomics (Canada), Cloud Pharmaceuticals, Inc (US), Microsoft corporation (US), Insilico Medicine (China), Cyclica (Canada), BenevolentAI (UK), and Exscientia (UK).

Segment Analysis

The global Artificial Intelligence in Drug Discovery market has been segmented based on Product and Service, Molecule Type, Technology, Indication, and Application.

On the basis of Product and Service, the market is segmented into software and services. In terms of revenue, the Artificial Intelligence in Drug Discovery Market was dominated by the services sector in 2022. This is brought on by the growing usage of AI services in the drug discovery industry as well as the increased demand for AI services among end users.

Based on Molecule Type, the global Artificial Intelligence in Drug Discovery market has been segmented into large molecule and small molecule. The market was dominated by large molecules in 2022, but during the forecast period of 2023–2032, tiny molecules are expected to rise more quickly.

Based on Technology, the global Artificial Intelligence in Drug Discovery market has been segmented into machine learning, deep learning, and others. In 2022, the deep learning segment led the market, and over the forecast period, 2023–2022, machine learning is anticipated to grow more quickly than deep learning.

Based on Indication, the global Artificial Intelligence in Drug Discovery market has been immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others. In 2022, the immuno-oncology category dominated the market. From 2023 to 2032, it is anticipated that the segment with the fastest growth will be neurodegenerative disorders.

Based on Application, the global Artificial Intelligence in Drug Discovery market has been target identification, candidate screening, de novo drug designing, drug optimization and repurposing, and preclinical testing. Target identification is anticipated to increase at a quicker rate during the projection period of 2023–2032 than preclinical testing, which dominated the market in 2022.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Artificial Intelligence in Drug Discovery Market Research Report

Regional Analysis

The global Artificial Intelligence in Drug Discovery market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Artificial Intelligence in Drug Discovery market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Artificial Intelligence in Drug Discovery market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Artificial Intelligence in Drug Discovery market comprises of Middle East, Africa, and Latin America.

The North America Artificial Intelligence in Drug Discovery Market dominated this market in 2022. This is brought on by the rising prevalence of chronic diseases, a sizable number of well-known startups, and rising investments in pharmaceutical R&D in the area.

Additionally, the second-largest market share for Artificial Intelligence in Drug Discovery is held by Europe. due to the increased demand for an AI-driven platform for drug discovery and the expanding occurrence of uncommon diseases in Europe.

Moreover, from 2023 to 2032, it's anticipated that the Asia-Pacific artificial intelligence in drug discovery market will expand at a high rate. This is a result of the increased disease burden and the massive adoption of AI capabilities by biopharmaceutical firms in the Asia-Pacific area.

China is also the birthplace of ID, and more Chinese biotechnology firms are collaborating with AI-driven businesses, which contributes to the market's expansion.

The Middle East, Africa, and Latin America are divided up under the heading of the Rest of the World. The above-mentioned areas' artificial intelligence drug discovery market is anticipated to expand due to increased pharmaceutical demand brought on by an increase in the prevalence of chronic and infectious diseases.

Key Findings of the Study

• The global Artificial Intelligence in Drug Discovery market is expected to reach USD 5.94 billion by 2032, at a CAGR of 29.83% during the forecast period.


• The North America Artificial Intelligence in Drug Discovery Market dominated this market in 2022.


• Based on Molecule Type, the market was dominated by large molecules in 2022.


• IBM (US), Alphabet Inc (US), Atomwise Inc (US), Deep Genomics (Canada), Cloud Pharmaceuticals, Inc (US), Microsoft corporation (US), and Insilico Medicine (China)